Refractory/relapsed chronic lymphocytic leukemia

Clinical trials for Refractory/relapsed chronic lymphocytic leukemia explained in plain language.

Never miss a new study

Get alerted when new Refractory/relapsed chronic lymphocytic leukemia trials appear

Sign up with your email to follow new studies for Refractory/relapsed chronic lymphocytic leukemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug ibrutinib shows promise for Hard-to-Treat blood cancers

Disease control Ongoing

This Phase 2 trial tests the drug ibrutinib in 154 people with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL). Participants take ibrutinib pills daily for 28-day cycles. The main goal is to se…

Matched conditions: REFRACTORY/RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA

Phase 2 • Sponsor: Kami Maddocks, MD • Aim: Disease control

Last updated Jun 27, 2026 12:06 UTC

Refractory/relapsed chronic lymphocytic leukemia

Get alerted when new Refractory/relapsed chronic lymphocytic leukemia trials appear

New drug ibrutinib shows promise for Hard-to-Treat blood cancers